2023
Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer
Cartmel B, Li F, Zhou Y, Gottlieb L, Lu L, Mszar R, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Risch H, Irwin M. Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer. Cancer Medicine 2023, 12: 15492-15503. PMID: 37269192, PMCID: PMC10417064, DOI: 10.1002/cam4.6187.Peer-Reviewed Original ResearchConceptsExercise interventionOvarian cancerTrial of exerciseExercise-induced changesMin/weekGroup differencesSubset of participantsCause mortalityExercise groupOverall survivalStudy armsCA 125Randomized trialsBlood biomarkersBlood drawBreast cancerClinical significanceIGF-1Effect model analysisSecondary analysisBeneficial effectsCancerBiomarkersTrialsWomenFolate Intake and Ovarian Cancer Risk among Women with Endometriosis: A Case–Control Study from the Ovarian Cancer Association Consortium
Gersekowski K, Ibiebele T, Group F, Doherty J, Harris H, Goodman M, Terry K, Wu A, Bandera E, Qin B, Ong J, Tyrer J, Dixon-Suen S, Modugno F, Risch H, Webb P. Folate Intake and Ovarian Cancer Risk among Women with Endometriosis: A Case–Control Study from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2023, 32: of1-of10. PMID: 37220873, PMCID: PMC10390886, DOI: 10.1158/1055-9965.epi-23-0121.Peer-Reviewed Original ResearchConceptsOvarian cancer riskHigh dietary folate intakeDietary folate intakeCase-control studyFolate intakeOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioMendelian randomizationSelf-reported endometriosisSupplemental folate intakeHigh folate intakeHigh folate dietCancer-promoting effectsPooled analysisFolate dietPrecancerous lesionsFolate statusEndometriosisIncrease riskCancerCancer typesLogistic regressionIntakeLifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficients
2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Benitez J, Berthet P, Białkowska K, Blanco AM, Blok MJ, Bonanni B, Boonen SE, Borg Å, Bozsik A, Bradbury AR, Brennan P, Brewer C, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Christensen LL, Chung WK, Claes KBM, Colas C, Collonge-Rame M, Cook J, Daly M, Davidson R, de la Hoya M, de Putter R, Delnatte C, Devilee P, Diez O, Ding Y, Domchek S, Dorfling C, Dumont M, Eeles R, Ejlertsen B, Engel C, Evans D, Faivre L, Foretova L, Fostira F, Friedlander M, Friedman E, Frost D, Ganz P, Garber J, Gehrig A, Gerdes A, Gesta P, Giraud S, Glendon G, Godwin A, Goldgar D, González-Neira A, Greene M, Gschwantler-Kaulich D, Hahnen E, Hamann U, Hanson H, Hentschel J, Hogervorst F, Hooning M, Horvath J, Hu C, Hulick P, Imyanitov E, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, John E, Joseph V, Karlan B, Kast K, Koudijs M, Kruse T, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Lesueur F, Liljegren A, Loud J, Lubiński J, Mai P, Manoukian S, Mari V, Mebirouk N, Meijers-Heijboer H, Meindl A, Mensenkamp A, Miller A, Montagna M, Mouret-Fourme E, Mukherjee S, Mulligan A, Nathanson K, Neuhausen S, Nevanlinna H, Niederacher D, Nielsen F, Nikitina-Zake L, Noguès C, Olah E, Olopade O, Ong K, O’Shaughnessy-Kirwan A, Osorio A, Ott C, Papi L, Park S, Parsons M, Pedersen I, Peissel B, Peixoto A, Peterlongo P, Pfeiler G, Phillips K, Prajzendanc K, Pujana M, Radice P, Ramser J, Ramus S, Rantala J, Rennert G, Risch H, Robson M, Rønlund K, Salani R, Schuster H, Senter L, Shah P, Sharma P, Side L, Singer C, Slavin T, Soucy P, Southey M, Spurdle A, Steinemann D, Steinsnyder Z, Stoppa-Lyonnet D, Sutter C, Tan Y, Teixeira M, Teo S, Thull D, Tischkowitz M, Tognazzo S, Toland A, Trainer A, Tung N, van Engelen K, van Rensburg E, Vega A, Vierstraete J, Wagner G, Walker L, Wang-Gohrke S, Wappenschmidt B, Weitzel J, Yadav S, Yang X, Yannoukakos D, Zimbalatti D, Offit K, Thomassen M, Couch F, Schmutzler R, Simard J, Easton D, Chenevix-Trench G, Antoniou A. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics In Medicine 2020, 22: 1653-1666. PMID: 32665703, PMCID: PMC7521995, DOI: 10.1038/s41436-020-0862-x.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerPathogenic variant carriersProspective cohortPolygenic risk scoresVariant carriersCancer riskRisk scoreStrong associationEOC riskHigh-grade serous epithelial ovarian cancerSerous epithelial ovarian cancerER-positive BCBRCA2 pathogenic variantsCarriers of BRCA1Absolute risk differenceEpithelial ovarian cancer riskGeneral population estimatesOvarian cancer riskHR estimatesBRCA2 pathogenic variant carriersBRCA1 carriersBRCA1/2 carriersOvarian cancerBC riskEstrogen receptorAssociation Between Breastfeeding and Ovarian Cancer Risk
Babic A, Sasamoto N, Rosner BA, Tworoger SS, Jordan SJ, Risch HA, Harris HR, Rossing MA, Doherty JA, Fortner RT, Chang-Claude J, Goodman MT, Thompson PJ, Moysich KB, Ness RB, Kjaer SK, Jensen A, Schildkraut JM, Titus LJ, Cramer DW, Bandera EV, Qin B, Sieh W, McGuire V, Sutphen R, Pearce CL, Wu AH, Pike M, Webb PM, Modugno F, Terry KL. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology 2020, 6: e200421. PMID: 32239218, PMCID: PMC7118668, DOI: 10.1001/jamaoncol.2020.0421.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive ovarian cancerEpithelial ovarian cancerOvarian cancerCancer riskLower riskOdds ratioLogistic regressionHigh-grade serous subtypeHistotype-specific associationsMultivariable logistic regressionCase-control studyOvarian Cancer Association ConsortiumPolytomous logistic regressionParous womenEndometrioid cancerModifiable factorsPooled analysisSerous subtypeMAIN OUTCOMEBreastfeedingMore monthsOverall associationLethal typeCancer
2019
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Group A, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Lindström S, Terry K. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2019, 48: 822-830. PMID: 31211375, PMCID: PMC6659359, DOI: 10.1093/ije/dyz113.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvarian cancer riskOvarian Cancer Association ConsortiumSelf-reported polycystic ovary syndromeInvasive ovarian cancerOvarian cancerCancer riskOvary syndromeInverse associationOral contraceptive useReproductive-aged womenBody mass indexSingle nucleotide polymorphismsStrong inverse associationComplex endocrine disorderObservational study resultsMendelian randomization studyEuropean ancestry womenEndometrioid tumorsMass indexDecreased riskEndocrine disordersSpecific histotypesContraceptive useAged womenShared heritability and functional enrichment across six solid cancers
Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubiński J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S. Shared heritability and functional enrichment across six solid cancers. Nature Communications 2019, 10: 431. PMID: 30683880, PMCID: PMC6347624, DOI: 10.1038/s41467-018-08054-4.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCase-Control StudiesColorectal NeoplasmsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHead and Neck NeoplasmsHumansInheritance PatternsLung NeoplasmsMaleMental DisordersNeoplasm ProteinsOvarian NeoplasmsPhenotypePolymorphism, Single NucleotideProstatic NeoplasmsSmokingWhite PeopleConceptsHead/neck cancerHead/neckColorectal cancerLung cancerNeck cancerOvarian cancerProstate cancerSolid cancersGenetic correlationsPsychiatric diseasesSolid tumorsMultiple cancersCancerCancer etiologyCancer typesBreastFunctional enrichment analysisMetabolic characteristicsGenome-wide association study summary statisticsLungDiseaseSignificant genetic correlationsEuropean ancestryEnrichment analysisFunctional enrichment
2018
Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies
Peres LC, Risch H, Terry KL, Webb P, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Manichaikul A, Abbott SE, Camacho F, Jordan SJ, Nagle CM, Group A, Rossing M, Doherty J, Modugno F, Moysich K, Ness R, Berchuck A, Cook L, Le N, Brooks-Wilson A, Sieh W, Whittemore A, McGuire V, Rothstein J, Anton-Culver H, Ziogas A, Pearce C, Tseng C, Pike M, Schildkraut J, Consortium O. Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal Of Epidemiology 2018, 47: 1011-1011. PMID: 29584862, PMCID: PMC6005044, DOI: 10.1093/ije/dyy054.Peer-Reviewed Original ResearchAdult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study
Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W, Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Rzepecka IK, Webb PM, on behalf of the Ovarian Cancer Association Consortium. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal Of Cancer 2018, 118: 1123-1129. PMID: 29555990, PMCID: PMC5931085, DOI: 10.1038/s41416-018-0011-3.Peer-Reviewed Original ResearchConceptsOvarian cancer riskMendelian randomisationOdds ratioOvarian cancerCancer riskStudy-specific odds ratiosConfidence intervalsMendelian randomisation studyBackgroundObservational studiesOvarian carcinogenesisRisk scoreAdult heightConsortium studySingle nucleotide polymorphismsRiskCancerGenetic propensityPolycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Group O, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Wentzensen N, Kotsopoulos J, Narod S, Phelan C, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Terry K, Consortium O. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2018, 27: 174-182. PMID: 29141849, PMCID: PMC5877463, DOI: 10.1158/1055-9965.epi-17-0655.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerPolycystic ovary syndromeOvarian cancer riskMenstrual cycle lengthOvarian cancerCancer riskDecreased riskSelf-reported polycystic ovary syndromeLogistic regressionCycle lengthStudy-specific ORsIrregular menstrual cyclesSerous borderline tumorsRisk factor associationsCase-control studyOvarian cancer histotypesPolytomous logistic regressionMucinous tumorsOvary syndromeBorderline tumorsHistologic subtypeOvarian diseaseMenstrual cycleCancer histotypesHistotype
2017
Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies
Peres LC, Risch H, Terry KL, Webb PM, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Manichaikul A, Abbott SE, Camacho F, Jordan SJ, Nagle CM, Group A, Rossing M, Doherty J, Modugno F, Moysich K, Ness R, Berchuck A, Cook L, Le N, Brooks-Wilson A, Sieh W, Whittemore A, McGuire V, Rothstein J, Anton-Culver H, Ziogas A, Pearce C, Tseng C, Pike M, Schildkraut J, Consortium T. Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal Of Epidemiology 2017, 47: 460-472. PMID: 29211900, PMCID: PMC5913601, DOI: 10.1093/ije/dyx252.Peer-Reviewed Original ResearchConceptsAfrican American Cancer Epidemiology StudyRace/ethnicityCase-control studyOvarian Cancer Association ConsortiumOdds ratioLargest odds ratioRisk factorsFamily historyEOC riskFirst-degree family historyModifiable risk factorsMultivariable logistic regressionOvarian cancer incidenceRisk factor associationsCancer Epidemiology StudyEthnic differencesAsian/Pacific IslandersOvarian cancer etiologyBlack womenInvasive EOCPooled analysisEpidemiological characteristicsCancer incidenceOvarian cancerHigh prevalenceAssessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study
Ong J, Hwang L, Cuellar-Partida G, Martin N, Chenevix-Trench G, Quinn M, Cornelis M, Gharahkhani P, Webb P, MacGregor S, Ong J, Hwang L, Cuellar-Partida G, Bryne E, Fasching P, Hein A, Burghaus S, Beckmann M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Swerdlow A, Jones M, Orr N, Schoemaker M, Edwards D, Brenton J, Benítez J, García M, Rodriguez-Antona C, Rossing M, Fortner R, Riboli E, Chang-Claude J, Eilber U, Wang-Gohrke S, Yannoukakos D, Goodman M, Bogdanova N, Dörk T, Duerst M, Hillemanns P, Runnebaum I, Antonenkova N, Butzow R, Nevanlinna H, Pelttari L, Edwards R, Kelley J, Modugno F, Moysich K, Ness R, Cannioto R, Heitz F, Karlan B, Olsson H, Kjaer S, Jensen A, Giles G, Bruinsma F, Hildebrandt M, Liang D, Wu X, Le Marchand L, Setiawan V, Permuth J, Bisogna M, Dao F, Levine D, Cramer D, Terry K, Tworoger S, Stampfer M, Willet W, Missmer S, Bjorge L, Kopperud R, Bischof K, Thomsen L, Kiemeney L, Massuger L, Pejovic T, Brooks-Wilson A, Olson S, McGuire V, Rothstein J, Sieh W, Whittemore A, Cook L, Le N, Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Wentzensen N, Brinton L, Trabert B, Lissowska J, Høgdall E, Høgdall C, Sandler D, Wolk A, Tyrer J, Song H, Eccles D, Campbell I, Glasspool R, McNeish I, Paul J, Siddiqui N, Sutphen R, McLaughlin J, Phelan C, Anton-Culver H, Ziogas A, May T, Gayther S, Gentry-Maharaj A, Menon U, Ramus S, Wu A, Huntsman D, deFazio A, Dansonka-Mieszkowska A, Kupryjanczyk J, Moes-Sosnowska J, Szafron L, Cunningham J, Winham S, Risch H, Goode E, Schildkraut J, Pearce C, Berchuck A, Pharoah P, Martin N, Chenevix-Trench G, Quinn M, Cornelis M, Gharahkhani P, Webb P, MacGregor S. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2017, 47: 450-459. PMID: 29186515, PMCID: PMC6186013, DOI: 10.1093/ije/dyx236.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian Cancer Association ConsortiumOvarian cancerObservational studyCoffee consumptionEOC riskEOC casesHigh-grade serous epithelial ovarian cancerMendelian randomizationSerous epithelial ovarian cancerModerate coffee consumptionHigh-grade serous casesMendelian randomization studyTwo-sample Mendelian randomizationAdditional cupProtective associationCaffeine consumptionHealth outcomesEarlier observational studiesRandomization studySerous casesStrong associationSingle nucleotide polymorphismsCaffeine levelsCancerMenstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium
Babic A, Harris HR, Vitonis AF, Titus LJ, Jordan SJ, Webb PM, Group A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Moysich K, Ness R, Kjaer S, Schildkraut J, Berchuck A, Pearce C, Wu A, Cramer D, Terry K. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. International Journal Of Cancer 2017, 142: 460-469. PMID: 28833087, PMCID: PMC7580880, DOI: 10.1002/ijc.31010.Peer-Reviewed Original ResearchConceptsSevere menstrual painMenstrual painOvarian cancerOdds ratioHistologic subtypePotential confoundersIncreased ovarian cancer riskLogistic regressionSpecific histologic subtypesCommon gynecological conditionEpithelial ovarian cancerMultivariate logistic regressionOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumInternational pooled analysisUse of hormonesSevere painGynecological conditionsProspective studyPooled analysisClear cellsUndiagnosed endometriosisCancer riskMultinomial logistic regressionHistory of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva AN, Consortium JL, Freudenheim KH, Eng RA, Cannioto G, Friel JB, Szender B, Segal K, Odunsi P, Mayor B, Diergaarde E, Zsiros LE, Kelemen M, Köbel H, Steed A, deFazio SJ, Group PA, Jordan MW, Fasching HA, Beckmann MA, Risch JA, Rossing J, Doherty MT, Chang-Claude T, Goodman R, Dörk F, Edwards RB, Modugno K, Ness M, Matsuo BY, Mizuno EL, Karlan SK, Goode E, Kjær JM, Høgdall KL, Schildkraut DW, Terry EV, Cramer LE, Bandera LA, Paddock LFAG, Kiemeney R, Massuger H, Sutphen A, Anton-Culver U, Ziogas SA, Menon SJ, Gayther A, Ramus CL, Gentry-Maharaj AH, Pearce J, Wu A, Kupryjanczyk PM, Jensen KB, Webb P, Moysich K. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1470-1473. PMID: 28864456, PMCID: PMC5649363, DOI: 10.1158/1055-9965.epi-17-0367.Peer-Reviewed Original ResearchConceptsProgression-free survivalHistory of endometriosisStage of diseaseOvarian cancer patientsOvarian cancer outcomeCancer outcomesCancer patientsCox proportional hazards regression modelProportional hazards regression modelsHazards regression modelsInvasive ovarian carcinomasOvarian cancer prognosisOvarian Cancer Association ConsortiumPooled HRsConcurrent comorbiditiesHistologic subtypeOvarian carcinomaChronic diseasesOvarian cancerWeight statusNeurologic diseaseCancer prognosisComorbiditiesTreatment efficacyNeurological diseasesQuantifying the Genetic Correlation between Multiple Cancer Types
Lindström S, GECCO and the GAME-ON Network: CORECT D, Finucane H, Bulik-Sullivan B, Schumacher F, Amos C, Hung R, Rand K, Gruber S, Conti D, Permuth J, Lin H, Goode E, Sellers T, Amundadottir L, Stolzenberg-Solomon R, Klein A, Petersen G, Risch H, Wolpin B, Hsu L, Huyghe J, Chang-Claude J, Chan A, Berndt S, Eeles R, Easton D, Haiman C, Hunter D, Neale B, Price A, Kraft P. Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1427-1435. PMID: 28637796, PMCID: PMC5582139, DOI: 10.1158/1055-9965.epi-17-0211.Peer-Reviewed Original ResearchConceptsColorectal cancerLung cancerRisk factorsBreast cancerRare high-penetrance mutationsCancer typesBody mass indexSpecific genetic risk factorsGenetic risk factorsHigh-penetrance mutationsMass indexControl subjectsOvarian cancerObservational studyProstate cancerNoncancer diseasesGenome-wide association studiesCancerDistinct cancersPrevious observational studiesAssociation studiesColorectalLungSummary statistics dataModest genetic correlationRandomized Trial of Exercise on Quality of Life in Women With Ovarian Cancer: Women’s Activity and Lifestyle Study in Connecticut (WALC)
Zhou Y, Cartmel B, Gottlieb L, Ercolano EA, Li F, Harrigan M, McCorkle R, Ligibel JA, von Gruenigen VE, Gogoi R, Schwartz PE, Risch HA, Irwin ML. Randomized Trial of Exercise on Quality of Life in Women With Ovarian Cancer: Women’s Activity and Lifestyle Study in Connecticut (WALC). Journal Of The National Cancer Institute 2017, 109: djx072. PMID: 30053074, PMCID: PMC6515522, DOI: 10.1093/jnci/djx072.Peer-Reviewed Original ResearchConceptsCancer-related fatigueOvarian cancer survivorsOvarian cancerCancer survivorsExercise interventionPhysical HRQoLCommunity-based exercise programSix-month RCTHealth-related qualityPrimary care providersTreatment side effectsGroup differencesSix-month assessmentQuality of lifeExercise armOverall survivalHigher HRQoLExercise programMental HRQOLRandomized trialsLifestyle StudyControl armFatigue scoresHRQoLPhysical activityAssociation Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study
Haycock P, Burgess S, Nounu A, Zheng J, Okoli G, Bowden J, Wade K, Timpson N, Evans D, Willeit P, Aviv A, Gaunt T, Hemani G, Mangino M, Ellis H, Kurian K, Pooley K, Eeles R, Lee J, Fang S, Chen W, Law M, Bowdler L, Iles M, Yang Q, Worrall B, Markus H, Hung R, Amos C, Spurdle A, Thompson D, O’Mara T, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret N, Lund E, Duell E, Canzian F, Severi G, Overvad K, Gunter M, Tumino R, Svenson U, van Rij A, Baas A, Bown M, Samani N, van t’Hof F, Tromp G, Jones G, Kuivaniemi H, Elmore J, Johansson M, Mckay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci P, Neale R, Olson S, Gallinger S, Li D, Petersen G, Risch H, Klein A, Han J, Abnet C, Freedman N, Taylor P, Maris J, Aben K, Kiemeney L, Vermeulen S, Wiencke J, Walsh K, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis G, SanGiovanni J, Li Y, Mijatovic V, Sapkota Y, Low S, Zondervan K, Montgomery G, Nyholt D, van Heel D, Hunt K, Arking D, Ashar F, Sotoodehnia N, Woo D, Rosand J, Comeau M, Brown W, Silverman E, Hokanson J, Cho M, Hui J, Ferreira M, Thompson P, Morrison A, Felix J, Smith N, Christiano A, Petukhova L, Betz R, Fan X, Zhang X, Zhu C, Langefeld C, Thompson S, Wang F, Lin X, Schwartz D, Fingerlin T, Rotter J, Cotch M, Jensen R, Munz M, Dommisch H, Schaefer A, Han F, Ollila H, Hillary R, Albagha O, Ralston S, Zeng C, Zheng W, Shu X, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd M, Davila S, Xie G, Siminovitch K, Bei J, Zeng Y, Försti A, Chen B, Landi S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma S, Foo J, Liu J, Kim J, Cox D, Delattre O, Mirabeau O, Skibola C, Tang C, Garcia-Barcelo M, Chang K, Su W, Chang Y, Martin N, Gordon S, Wade T, Lee C, Kubo M, Cha P, Nakamura Y, Levy D, Kimura M, Hwang S, Hunt S, Spector T, Soranzo N, Manichaikul A, Barr R, Kahali B, Speliotes E, Yerges-Armstrong L, Cheng C, Jonas J, Wong T, Fogh I, Lin K, Powell J, Rice K, Relton C, Martin R, Smith G. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncology 2017, 3: 636-651. PMID: 28241208, PMCID: PMC5638008, DOI: 10.1001/jamaoncol.2016.5945.Peer-Reviewed Original ResearchConceptsGermline genetic variationGenomewide association studiesGenetic variationSingle nucleotide polymorphismsTelomere lengthStem cell divisionSummary association statisticsGermline genetic variantsCell divisionAssociation studiesLonger telomeresGenetic variantsNucleotide polymorphismsAssociation statisticsTelomeresSummary dataLung adenocarcinomaKidney cancerNon-neoplastic diseasesPolymorphismVariationTissue sitesCancerOvarian cancerDivisionUse of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium
Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Ness R, Edwards R, Jensen A, Kjær S, Høgdall E, Berchuck A, Cramer D, Terry K, Poole E, Bandera E, Paddock L, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Pearce C, Wu A, Pike M, Webb P. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal Of Cancer 2017, 116: 1223-1228. PMID: 28350790, PMCID: PMC5418444, DOI: 10.1038/bjc.2017.68.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsDisease-specific survivalOvarian cancer survivalAnalgesic useCancer survivalOvarian cancerInvasive epithelial ovarian cancerCommon analgesic medicationsPost-diagnosis usePre-diagnosis useRegular analgesic useEpithelial ovarian cancerOvarian Cancer Association ConsortiumAnti-inflammatory drugsAnalgesic medicationOverall survivalImproved survivalPooled analysisCommon analgesicsSurvival advantageConsortium studyClear associationCancerSurvivalFurther investigationIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, Aravantinos G, Arnold N, Arun B, Arver B, Azzollini J, Balmaña J, Banerjee S, Barjhoux L, Barkardottir R, Bean Y, Beckmann M, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini M, Birrer M, Bjorge L, Black A, Blankstein K, Blok M, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury A, Brenton J, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys S, Caldes T, Caligo M, Campbell I, Cannioto R, Carney M, Cescon T, Chan S, Chang-Claude J, Chanock S, Chen X, Chiew Y, Chiquette J, Chung W, Claes K, Conner T, Cook L, Cook J, Cramer D, Cunningham J, D'Aloisio A, Daly M, Damiola F, Damirovna S, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny K, Diez O, Ding Y, Doherty J, Domchek S, Dorfling C, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici A, Ellis S, Elvira M, Eng K, Engel C, Evans D, Fasching P, Ferguson S, Ferrer S, Flanagan J, Fogarty Z, Fortner R, Fostira F, Foulkes W, Fountzilas G, Fridley B, Friebel T, Friedman E, Frost D, Ganz P, Garber J, García M, Garcia-Barberan V, Gehrig A, Gentry-Maharaj A, Gerdes A, Giles G, Glasspool R, Glendon G, Godwin A, Goldgar D, Goranova T, Gore M, Greene M, Gronwald J, Gruber S, Hahnen E, Haiman C, Håkansson N, Hamann U, Hansen T, Harrington P, Harris H, Hauke J, Hein A, Henderson A, Hildebrandt M, Hillemanns P, Hodgson S, Høgdall C, Høgdall E, Hogervorst F, Holland H, Hooning M, Hosking K, Huang R, Hulick P, Hung J, Hunter D, Huntsman D, Huzarski T, Imyanitov E, Isaacs C, Iversen E, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen U, John E, Johnatty S, Jones M, Kannisto P, Karlan B, Karnezis A, Kast K, Kennedy C, Khusnutdinova E, Kiemeney L, Kiiski J, Kim S, Kjaer S, Köbel M, Kopperud R, Kruse T, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson M, Lazaro C, Le N, Le Marchand L, Lee J, Lele S, Leminen A, Leroux D, Lester J, Lesueur F, Levine D, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu K, Lubinński J, Luccarini C, Lundvall L, Mai P, Mendoza-Fandiño G, Manoukian S, Massuger L, May T, Mazoyer S, McAlpine J, McGuire V, McLaughlin J, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp A, Merritt M, Milne R, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich K, Mulligan A, Musinsky J, Nathanson K, Nedergaard L, Ness R, Neuhausen S, Nevanlinna H, Niederacher D, Nussbaum R, Odunsi K, Olah E, Olopade O, Olsson H, Olswold C, O'Malley D, Ong K, Onland-Moret N, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon T, Paul J, Pearce C, Pedersen I, Peeters P, Peissel B, Peixoto A, Pejovic T, Pelttari L, Permuth J, Peterlongo P, Pezzani L, Pfeiler G, Phillips K, Piedmonte M, Pike M, Piskorz A, Poblete S, Pocza T, Poole E, Poppe B, Porteous M, Prieur F, Prokofyeva D, Pugh E, Pujana M, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez G, Rodríguez-Antona C, Romm J, Rookus M, Rossing M, Rothstein J, Rudolph A, Runnebaum I, Salvesen H, Sandler D, Schoemaker M, Senter L, Setiawan V, Severi G, Sharma P, Shelford T, Siddiqui N, Side L, Sieh W, Singer C, Sobol H, Song H, Southey M, Spurdle A, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell L, Sukiennicki G, Sutphen R, Sutter C, Swerdlow A, Szabo C, Szafron L, Tan Y, Taylor J, Tea M, Teixeira M, Teo S, Terry K, Thompson P, Thomsen L, Thull D, Tihomirova L, Tinker A, Tischkowitz M, Tognazzo S, Toland A, Tone A, Trabert B, Travis R, Trichopoulou A, Tung N, Tworoger S, van Altena A, Van Den Berg D, van der Hout A, van der Luijt R, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg E, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards D, Vergote I, Vierkant R, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb P, Weinberg C, Weitzel J, Wentzensen N, Whittemore A, Wijnen J, Wilkens L, Wolk A, Woo M, Wu X, Wu A, Yang H, Yannoukakos D, Ziogas A, Zorn K, Narod S, Easton D, Amos C, Schildkraut J, Ramus S, Ottini L, Goodman M, Park S, Kelemen L, Risch H, Thomassen M, Offit K, Simard J, Schmutzler R, Hazelett D, Monteiro A, Couch F, Berchuck A, Chenevix-Trench G, Goode E, Sellers T, Gayther S, Antoniou A, Pharoah P. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics 2017, 49: 680-691. PMID: 28346442, PMCID: PMC5612337, DOI: 10.1038/ng.3826.Peer-Reviewed Original ResearchMeSH KeywordsAllelesBRCA1 ProteinBRCA2 ProteinCarcinoma, Ovarian EpithelialFemaleGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMeta-Analysis as TopicMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsTelomere-Binding ProteinsConceptsNew susceptibility lociSusceptibility lociGenome-wide association studiesLarge genome-wide association studiesCandidate susceptibility genesRegulatory featuresAssociation studiesSusceptibility genesLociIntegrated analysisEpithelial ovarian cancer histotypesGenesOvarian cancer histotypesOvarian cancerCancer histotypesOBFC1Different histotypesEpithelial ovarian cancerIdentificationRisk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA, Group O. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecologic Oncology 2017, 145: 346-351. PMID: 28314588, DOI: 10.1016/j.ygyno.2017.02.032.Peer-Reviewed Original ResearchConceptsBRCA mutation carriersOvarian cancer patientsOvarian cancerBreast cancerMutation carriersPreventive mastectomyCancer patientsActuarial riskStage III/IV ovarian cancerUnaffected BRCA mutation carriersEarly-stage ovarian cancerBreast cancer incidenceStage ovarian cancerMutation-carrying patientsProportional hazards modelCause of mortalityImpact of mastectomyOvarian cancer diagnosisProbability of deathBreast surveillanceCause mortalityAnnual mortality rateClinical benefitBreast surgeryInternational registry